Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 6/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979801 | 0.85 | BCHE (0.41) | NOTUMDRD3ADRB1HCAR1DRD4 | |
| SCHEMBL2753419 | 0.79 | ALDH1A1 (0.34) | NOTUMHCAR1 | |
| SCHEMBL2751923 | 0.73 | NOTUM (0.44) | NOTUMP2RX7 | |
| SCHEMBL2751482 | 0.71 | RXRA (0.38) | HCAR1 | |
| SCHEMBL29090481 | 0.71 | NOTUM (0.43) | NOTUMDRD2DRD3ADRB1HCAR1 | |
| SCHEMBL4723225 | 0.71 | NPC1 (0.54) | NOTUMHCAR1 | |
| SCHEMBL696362 | 0.70 | TSHR (0.40) | ADRB1HCAR1 | |
| SCHEMBL1891782 | 0.70 | NOTUM (0.40) | NOTUMHCAR1 | |
| SCHEMBL3255936 | 0.70 | NPC1 (0.53) | NOTUMDRD2DRD3ADRB1P2RX7 | |
| SCHEMBL2094941 | 0.69 | NOTUM (0.41) | NOTUMDRD2DRD3ADRB1HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334683-B1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | MSD ITALIA SRL (IT) | 2017-03-22 | — | — | EP | disclosed |
| US-8470823-B2 | Saturated bicyclic heterocyclic derivatives as SMO antagonists | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20110183989-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | Instituto di Ricerche di Biologia Molecolare P. Ang | 2011-07-28 | — | — | US | disclosed |
| EP-2334683-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | BASF SE (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| WO-2010023480-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | TPMT, NISCH, PPA1 | NOTUM 772/4885DRD2 3190/4885DRD3 3052/4885 |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | PIR, PRDX4, PRDX2 | NOTUM 618/4885DRD2 3235/4885DRD3 2485/4885 |
| US-20110183989-A1 | SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS | SMO, SHH, GLI1 | NOTUM 1573/4885DRD2 4228/4885DRD3 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.